The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s biologic and biosimilar RA drugs market report forecasts the biologic and biosimilar RA drugs market size to grow to $15.19 Billion by 2027, with a CAGR (compound annual growth rate) of more than 4%.

Learn More On The Biologic And Biosimilar RA Drugs Market Report 2023 – https://www.thebusinessresearchcompany.com/report/biologic-and-biosimilar-ra-drugs-global-market-report

Biologic And Biosimilar RA Drugs Market Size Forecast
The global biologic and biosimilar RA drugs market is expected to grow from $12.08 billion in 2022 to $12.65 billion in 2023 at a compound annual growth rate (CAGR) of 4.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global biologic & biosimilar RA drugs market size is expected to grow to $15.19 billion in 2027 at a CAGR of 4.7%.

North America held the largest biologic and biosimilar RA drugs market share, and Asia-Pacific was the fastest-growing region in 2022.

Key Biologic And Biosimilar RA Drugs Market Driver ­– Rise In Older Population And Increasing Incidence Of Rheumatoid Arthritis
According to the globe Health Organisation (WHO), a United Nations specialised health agency based in Switzerland, there were around 1 billion individuals aged 60 and above in the globe in 2020, with this population predicted to grow to 1.4 billion by 2030 and 2.1 billion by 2050. Furthermore, the Centres for Disease Control and Prevention, a US-based governmental public health agency, predicts that the number of adults suffering from arthritis in the United States will rise to 78.4 million by 2040, with 34.6 million people experiencing arthritis-related activity limitations. As a result, the growing elderly population, combined with an increase in RA patients, is propelling the biologics and biosimilars RA drug market ahead.

Request for A Sample Of The Global Biologic And Biosimilar RA Drugs Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9255&type=smp

Key Biologic And Biosimilar RA Drugs Market Trend – Product Innovations
To maintain their market position, major firms in the biologics and biosimilars RA medicines industry are releasing novel products. For example, Bio-Thera Solutions, a Chinese biosimilar developer and producer, debuted QLETLI in January 2020. The new adalimumab biosimilar is the first to be licenced by China’s National Medical Products Administration (NMPA). It will help treat rheumatoid arthritis, ankylosing spondylitis, and plaque psoriasis.

Biologic And Biosimilar RA Drugs Market Segment
1) By Source: Microbial, Mammalian, Other Sources
2) By Disease: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Other Diseases
3) By Manufacturing: Outsourced, In-House
4) By Mode Of Purchase: Prescription Drugs, Over-The-Counter (OTC) Drugs
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Biologic And Biosimilar RA Drugs Market Major Players and Strategies
Major players in the biologic and biosimilar RA drugs market are Samsung BioLogics Co. Ltd., Amgen Inc., Novo Nordisk A/S, AbbVie Inc., Sanofi Pasteur, Johnson & Johnson Services Inc., Pfizer Inc., Merck & Co. Inc., Eli Lilly and Company, Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca PLC., Teva Pharmaceutical Industries Ltd., Fresenius Se & Co. KGaA, Stada Arzneimittel AG, Boehringer Ingelheim Pharmaceuticals Inc., and Gedeon Richter Plc.

Biocon, an India-based biopharmaceutical company, paid $3 billion for Viatris’ global biosimilars division in November 2022. The acquisition takes Biocon Biologics closer to patients, consumers, and payors by providing it with direct commercial capabilities and supporting infrastructure in a number of emerging and advanced markets. Viatris is a pharmaceutical business established in the United States that develops biosimilars for the treatment of rheumatoid arthritis and other disorders.

The Biologic And Biosimilar RA Drugs Global Market Report 2023 covers regional data on biologic and biosimilar RA drugs market size, biologic and biosimilar RA drugs market trends and drivers, opportunities, strategies, and biologic and biosimilar RA drugs market competitor analysis. The countries covered in the biologic and biosimilar RA drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Biologics and biosimilars are medications derived from living organisms such as living cells, bacteria, and other living animals. Biosimilars are biologics that share properties with an already approved biological molecule. These medications are used to treat rheumatoid arthritis.

View More Reports Related To The Biologic And Biosimilar RA Drugs Market –
Biosimilars Global Market Report 2023
Biosimilar Growth Hormones Global Market Report 2023
Biosimilar Monoclonal Antibodies Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: